The study finds that CHAI (Computational Histology AI) biomarkers stratify recurrence and progression outcomes independently and outperform current guideline-based risk stratification
June 13, 2025
A Digital Publication for the Practicing Medical Specialist, Industry Executive, & Investor
The study finds that CHAI (Computational Histology AI) biomarkers stratify recurrence and progression outcomes independently and outperform current guideline-based risk stratification